Short answer
Oncology Institute, Inc. (TOI) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Corporate rebrand to Starling Oncology, Inc., effective July 28, 2026.
Oncology Institute, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Corporate rebrand to Starling Oncology, Inc., effective July 28, 2026
- Nasdaq common-stock ticker changes to STLN beginning August 3, 2026
- Existing shareholder rights remain unchanged; no stockholder action required
- Common-stock CUSIP remains 68236X100, preserving security identification continuity
Item 7.01 · Regulation FD Disclosure
- Exhibit 99.1 furnished under Regulation FD, indicating supplemental company information for investors
- Exhibit content is not deemed filed or incorporated into Securities Act or Exchange Act filings absent specific reference
Item EX-99.1 · Exhibit EX-99.1
- Corporate rebrand to Starling Oncology, signaling evolution into an integrated, multi-market oncology platform
- Nasdaq ticker changes from “TOI” to “STLN” effective August 4, 2026
- Care continuity expected, with unchanged phone numbers, portals, and patient-provider contacts
- Platform reaches approximately 2.1 million patients through more than 100 locations across five states
- Network includes more than 400 employed and affiliated clinicians, supporting expanded value-based oncology delivery
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Oncology Institute, Inc. 8-K filings
Get the next TOI 8-K as it lands
Follow TOI for push alerts, or ask the research agent what this filing means.